{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T02:06:46Z","timestamp":1775873206247,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,29]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Splenic B-cell lymphoma\/leukemia with prominent nucleoli (SBLPN) is a new classification, which is so rare that it lacks clinical data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>An increased proportion of prolymphocytes (84%) in the bone marrow smear. Whole exon sequence analysis revealed a TP53 mutation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Combining the clinical features with laboratory test results led to a diagnosis of SBLPN which was made according to the 5th edition of the WHO classification of hematolymphoid tumors, although the patient was diagnosed with B-PLL when guided by the 4th edition of the WHO classification.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The use of Ibrutinib as an effective treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient was in complete remission after 5 months of Ibrutinib and then died of sudden aortic dissection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Ibrutinib was an effective regimen for SBLPN. Aortic dissection might be considered as a suspicious adverse reaction to Ibrutinib.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000036022","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T16:07:10Z","timestamp":1704816430000},"page":"e36022","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["An effective treatment and suspicious adverse reaction to Ibrutinib in a patient diagnosed with splenic B-cell lymphoma\/leukaemia with prominent nucleoli: A first case report"],"prefix":"10.1097","volume":"102","author":[{"given":"Mei-Xiao","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Hematology, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Sheng","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How i treat prolymphocytic leukemia.","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2019.06.001","article-title":"B and T cell prolymphocytic leukaemia.","volume":"32","author":"Cross","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms.","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms.","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-017-0581-x","article-title":"Prolymphocytic leukemia: new insights in diagnosis and in treatment.","volume":"19","author":"Collignon","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/jcp.42.6.567","article-title":"Proposals for the classification of chronic (mature) B and T lymphoid leukaemias French-American-British (FAB) cooperative group.","volume":"42","author":"Bennett","year":"1989","journal-title":"J Clin Pathol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2013-10-533869","article-title":"B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma.","volume":"124","author":"van der Velden","year":"2014","journal-title":"Blood"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.1997.15.1.37","article-title":"Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia.","volume":"15","author":"Saven","year":"1997","journal-title":"J Clin Oncol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/10428199909093739","article-title":"B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course.","volume":"33","author":"Shvidel","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbmt.2009.11.021","article-title":"Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.","volume":"16","author":"Kalaycio","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12185-014-1505-2","article-title":"Successful allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for B-cell prolymphocytic leukemia in partial remission.","volume":"99","author":"Arima","year":"2014","journal-title":"Int J Hematol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3109\/10428194.2011.631638","article-title":"Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.","volume":"53","author":"Seiffert","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances.","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for chronic lymphocytic leukemia with TP53 alterations.","volume":"383","author":"Ahn","year":"2020","journal-title":"N Engl J Med"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL.","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.14224","article-title":"Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.","volume":"179","author":"Gordon","year":"2017","journal-title":"Br J Haematol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"E108","DOI":"10.1002\/ajh.25733","article-title":"Initial treatment of B-cell prolymphocytic leukemia with ibrutinib.","volume":"95","author":"Moore","year":"2020","journal-title":"Am J Hematol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/10428194.2017.1347653","article-title":"Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.","volume":"59","author":"Damlaj","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1007\/s10637-020-00902-9","article-title":"Effective upfront treatment with low-dose ibrutinib for a patient with B cell prolymphocytic leukemia.","volume":"38","author":"Oka","year":"2020","journal-title":"Invest New Drugs"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1042\/CS20200305","article-title":"Cardiotoxic effects of angiogenesis inhibitors.","volume":"135","author":"Dobbin","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamaoncol.2021.0210","article-title":"Association between antiangiogenic drugs used for cancer treatment and artery dissections or aneurysms.","volume":"7","author":"Guyon","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:23:39Z","timestamp":1746318219000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,29]]},"references-count":22,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036022","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,29]]}}}